Glaxo, XenoPort Drug To Get Longer FDA Review
Stock quotes in this article:
XNPT
NEW YORK (AP) GlaxoSmithKline and XenoPort Inc. said Tuesday the Food and Drug Administration extended the review date of the company's potential restless leg syndrome treatment to Feb. 9.
The companies had originally expected the FDA to complete its review of GSK1838262, also called XP13512, by Nov. 9. The FDA had determined that the company needs to submit a risk evaluation and mitigation strategy. The agency now needs more time to review that plan. XenoPort is based in Santa Clara, Calif., and GlaxoSmithKline is headquartered in London. Shares of Glaxo fell 2 cents to close at $41.29 while shares of XenoPort fell $1.10 to close at $16.20.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,433.71 | 1,105.65 | 2,169.18 | 33.17 |
Oil *
76.42
|
|
DOWN
17.24
|
DOWN
0.59
|
DOWN
6.83
|
DOWN
0.47
|
10 Yr
3.32%
SPDR Gold
114.73
|
|
-0.16%
|
-0.05%
|
-0.31%
|
-1.40%
|
Data delayed 20 minutes |
